Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link
NEW YORK (
) has been upgraded by TheStreet Ratings from hold to buy. The company's strengths can be seen in multiple areas, such as its growth in earnings per share, increase in net income, revenue growth, good cash flow from operations and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity.
- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
Highlights from the ratings report include:
- QIAGEN NV has improved earnings per share by 41.7% in the most recent quarter compared to the same quarter a year ago. The company has demonstrated a pattern of positive earnings per share growth over the past year. We feel that this trend should continue. During the past fiscal year, QIAGEN NV increased its bottom line by earning $0.54 versus $0.41 in the prior year. This year, the market expects an improvement in earnings ($1.02 versus $0.54).
- The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Life Sciences Tools & Services industry. The net income increased by 39.6% when compared to the same quarter one year prior, rising from $29.16 million to $40.70 million.
- Despite its growing revenue, the company underperformed as compared with the industry average of 7.2%. Since the same quarter one year prior, revenues slightly increased by 5.8%. This growth in revenue appears to have trickled down to the company's bottom line, improving the earnings per share.
- Net operating cash flow has increased to $82.94 million or 10.69% when compared to the same quarter last year. In addition, QIAGEN NV has also modestly surpassed the industry average cash flow growth rate of 9.61%.
- The strong earnings growth this company has enjoyed -- up -- has apparently played a role in driving up its share price by a solid 27.11%. In addition, the rise in the general market has likely contributed to this stock's strong performance during this past year.We feel that the stock's sharp appreciation over the last year has driven it to a price level which is now somewhat expensive compared to the rest of its industry. The other strengths this company shows, however, justify the higher price levels.
QIAGEN N.V., through its subsidiaries, provides sample and assay technologies worldwide. The company has a P/E ratio of 43.7, above the S&P 500 P/E ratio of 17.7. Qiagen has a market cap of $5.53 billion and is part of the services sector and diversified services industry. Shares are up 30% year to date as of the close of trading on Friday.
You can view the full
or get investment ideas from our
Disclosure: TheStreet's editorial policy prohibits staff editors, reporters and analysts from holding positions in any individual stocks.